MENU
+Compare
ENTA
Stock ticker: NASDAQ
AS OF
Aug 26 closing price
Price
$8.65
Change
-$0.01 (-0.12%)
Capitalization
184.92M

ENTA Enanta Pharmaceuticals Forecast, Technical & Fundamental Analysis

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases... Show more

Industry: #Biotechnology
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ENTA with price predictions
Aug 26, 2025

ENTA sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ENTA moved above the 200-day moving average on August 01, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 14, 2025. You may want to consider a long position or call options on ENTA as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ENTA just turned positive on August 15, 2025. Looking at past instances where ENTA's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

ENTA moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ENTA crossed bullishly above the 50-day moving average on August 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTA advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 182 cases where ENTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ENTA moved out of overbought territory on August 21, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ENTA broke above its upper Bollinger Band on August 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ENTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.335) is normal, around the industry mean (19.605). P/E Ratio (0.000) is within average values for comparable stocks, (54.592). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.646). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (2.845) is also within normal values, averaging (305.338).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ENTA is expected to report earnings to rise 20.00% to -101 cents per share on November 17

Enanta Pharmaceuticals ENTA Stock Earnings Reports
Q3'25
Est.
$-1.02
Q2'25
Missed
by $0.01
Q1'25
Beat
by $0.10
Q4'24
Beat
by $0.22
Q3'24
Missed
by $0.20
The last earnings report on August 11 showed earnings per share of -85 cents, missing the estimate of -83 cents. With 89.38K shares outstanding, the current market capitalization sits at 184.92M.
A.I. Advisor
published General Information

General Information

a developer of drugs and other pharmaceuticals products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Arsenal Street
Phone
+1 617 607-0800
Employees
145
Web
https://www.enanta.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ILLMF1.120.02
+1.91%
illumin Holdings Inc.
HSNGF14.27N/A
N/A
Hang Seng Bank Ltd.
MITUY12.55N/A
N/A
Mitsui Chemicals Inc.
TMOAY2.80-0.24
-7.89%
Tomtom NV
PRPS0.43-0.09
-17.07%
PROPELLUS INC.

ENTA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-0.12%
ALEC - ENTA
40%
Loosely correlated
+0.85%
BEAM - ENTA
38%
Loosely correlated
+1.22%
ADCT - ENTA
36%
Loosely correlated
+2.59%
FATE - ENTA
35%
Loosely correlated
+1.83%
VRDN - ENTA
35%
Loosely correlated
+0.48%
More